STOCK TITAN

Protara Therapeutics Inc - TARA STOCK NEWS

Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.

Protara Therapeutics Inc (TARA) is a clinical-stage biotechnology company developing transformative therapies for cancer and rare diseases. This page provides investors and industry observers with timely updates on clinical trials, regulatory milestones, and corporate developments.

Access comprehensive coverage of TARA's investigational cell therapy TARA-002 for lymphatic malformations and IV Choline Chloride research. Our news collection features press releases, peer-reviewed data publications, and strategic partnership announcements.

Key updates include progress reports on:

• Clinical trial phases
• FDA designations
• Scientific conference presentations
• Intellectual property developments

Bookmark this page for centralized access to Protara's latest advancements in immunopotentiator therapies and metabolic replacement solutions. Monitor critical updates affecting the company's position in the oncology and rare disease treatment landscapes.

Rhea-AI Summary

Protara Therapeutics (TARA) provided a business update and financial results for Q1 2021, highlighting strong cash reserves of $155 million as of March 31, 2021. The company is on track to file an Investigational New Drug (IND) application and initiate a Phase 1 trial for TARA-002 targeting non-muscle invasive bladder cancer (NMIBC) by year-end 2021. The research and development expenses rose 125% to $7 million due to costs related to TARA-002, while general administrative expenses decreased. Protara reported a net loss of $13.5 million or $1.20 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
-
Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA) announced plans for an additional clinical study to support their Biologics License Application for TARA-002, targeting Lymphatic Malformations (LMs). Based on FDA feedback, the company will conduct large-scale GMP manufacturing comparability in late 2021 and initiate a pediatric clinical study pending alignment with the FDA. TARA-002 is derived from the same cell bank as OK-432, an approved treatment in Japan and Taiwan. Protara aims to deliver the first FDA-approved drug for LMs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.41%
Tags
none
-
Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA) has granted inducement non-qualified stock options for 120,000 shares to Dr. Martín Sebastian Olivo, the new Chief Medical Officer. The options have an exercise price of $15.30 per share, aligning with Protara's closing price as of April 19, 2021. Vesting occurs over four years, with 25% vesting after one year and the remainder vesting monthly. This award, approved by the Compensation Committee, aligns with NASDAQ Listing Rule 5635(c)(4). Protara is focused on developing therapies for cancer and rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
none
Rhea-AI Summary

Protara Therapeutics, Inc. (Nasdaq: TARA) announced the immediate appointment of Dr. Martín Sebastian Olivo as Chief Medical Officer. With over 15 years in oncology research and global drug development, Dr. Olivo previously led clinical development for Gilead Sciences' breast cancer program. His expertise is expected to significantly impact Protara's lead product, TARA-002, for treating non-muscle invasive bladder cancer and lymphatic malformations. Dr. Olivo's experience is anticipated to enhance the company's strategic objectives in developing transformative therapies for cancer and rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
management
-
Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA) announced significant advancements in its clinical pipeline, particularly for TARA-002 targeting non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Phase 1 study for NMIBC is expected to begin by year-end 2021, with cash reserves of $169M as of December 31, 2020. R&D expenses surged to $12M in 2020, reflecting growth in clinical programs. However, Protara reported a net loss of $34M, or $4.70 per share, for the year, compared to a $7.8M loss in 2019. The company remains optimistic about its future trajectory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
-
Rhea-AI Summary

Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 10:00am ET. The event will be held virtually, and a live audio webcast will be accessible on the company's website. Protara focuses on developing transformative therapies for cancer and rare diseases, with lead programs including TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
conferences
Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA) has announced its participation in two virtual investor conferences. The first is the Guggenheim Healthcare Talks 2021 Oncology Days, scheduled for February 11, 2021, at 9:30 AM ET. The second event is the Cowen 41st Annual Health Care Conference on March 3, 2021, at 1:20 PM ET. Both presentations will be accessible via the Events and Presentations section of Protara's website and archived for 90 days. Protara focuses on innovative therapies for cancer and rare diseases, notably TARA-002 for bladder cancer and IV Choline Chloride for liver disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
conferences
-
Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA) has promoted Jacqueline Zummo, Ph.D., MPH, MBA, from Senior Vice President to Chief Scientific Operations Officer. As a co-founder, Zummo has significantly contributed to the company's advancements, including its lead program TARA-002 for treating non-muscle invasive bladder cancer. With over 15 years of experience in the biopharmaceutical sector, Zummo is expected to drive the growth of Protara's strategies and enhance patient care. The company remains committed to addressing unmet needs in cancer and rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
management
-
Rhea-AI Summary

Protara Therapeutics, Inc. (Nasdaq: TARA) announced the grant of inducement non-qualified stock options totaling 41,500 shares to two new employees. The options have an exercise price of $22.45, which reflects the company's closing trading price on December 1, 2020, the grant date. Vested shares will occur over four years, with an initial 25% vesting on the one-year anniversary of each employee's start date, followed by monthly vesting. This award was approved by the Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
Rhea-AI Summary

Protara Therapeutics, Inc. (Nasdaq: TARA) has announced participation in two upcoming virtual investor conferences in December 2020. The events include the Piper Sandler 32nd Annual Virtual Healthcare Conference and the Evercore ISI 3rd Annual HealthCONx Virtual Conference, where Protara will present on December 3, 2020, at 12:10 PM ET. A live webcast of the Evercore presentation will be available on the company's website, and a replay of the Piper fireside chat is currently accessible. Protara is focused on transformative therapies for cancer and rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
Protara Therapeutics Inc

Nasdaq:TARA

TARA Rankings

TARA Stock Data

147.07M
35.39M
3.48%
86.65%
8.08%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK